Literature DB >> 21508697

Uterine papillary serous carcinoma.

Kathleen N Moore1, Amanda Nickles Fader.   

Abstract

Uterine papillary serous carcinoma (UPSC) is a histologic variant of endometrial cancer that accounts for only 10% of new cases of uterine cancer but is responsible for 40% of deaths from the disease. UPSC is an aggressive tumor with a predilection for early spread beyond the uterus. Treatment for UPSC typically entails surgery and in most women is followed by multimodality adjuvant therapy. In this review, we describe the epidemiology, natural history, treatment, and outcome of UPSC.

Entities:  

Mesh：

Year:  2011        PMID： 21508697     DOI： 10.1097/GRF.0b013e318218c755

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN： 0009-9201            Impact factor:   2.190


  34 in total

1.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

Review 2.  The emerging genomic landscape of endometrial cancer.

Authors:  Matthieu Le Gallo; Daphne W Bell
Journal:  Clin Chem       Date:  2013-10-29       Impact factor: 8.327

3.  An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Authors:  Casey M Cosgrove; David L Tritchler; David E Cohn; David G Mutch; Craig M Rush; Heather A Lankes; William T Creasman; David S Miller; Nilsa C Ramirez; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Cynthia Timmers; Adrian A Suarez; Richard J Zaino; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2017-11-11       Impact factor: 5.482

4.  Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Authors:  Summer B Dewdney; Nora T Kizer; Abegail A Andaya; Sheri A Babb; Jingqin Luo; David G Mutch; Amy P Schmidt; Louise A Brinton; Russell R Broaddus; Nilsa C Ramirez; Phyllis C Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L Judson; Robert S Mannel; Shashikant B Lele; David M O'Malley; Paul J Goodfellow
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13

5.  Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.

Authors:  Derman Basaran; Shaina Bruce; Emeline M Aviki; Jennifer J Mueller; Vance A Broach; Karen Cadoo; Robert A Soslow; Kaled M Alektiar; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2019-11-16       Impact factor: 5.482

6.  Factors prognostic of survival in advanced-stage uterine serous carcinoma.

Authors:  Laura L Holman; Navdeep Pal; David A Iglesias; Pamela T Soliman; Nyla Balakrishnan; Ann Klopp; Russell R Broaddus; Nicole D Fleming; Mark F Munsell; Karen H Lu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2017-04-30       Impact factor: 5.482

7.  Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Authors:  Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2017-09-13       Impact factor: 6.261

8.  Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.

Authors:  Salvatore Lopez; Emiliano Cocco; Jonathan Black; Stefania Bellone; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Carlton L Schwab; Diana P English; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Corrado Terranova; Roberto Angioli; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2015-09-02       Impact factor: 6.261

Review 9.  Type I and II endometrial cancers: have they different risk factors?

Authors:  Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

10.  Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.

Authors:  Shaomin Hu; Jeff L Hinson; Rahul Matnani; Michael L Cibull; Rouzan G Karabakhtsian
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.